<?xml version="1.0" encoding="UTF-8"?>
<project>
  <language>en</language>
  <availableLanguages>en</availableLanguages>
  <rcn>274743</rcn>
  <id>101199997</id>
  <acronym>A-PONTE</acronym>
  <teaser>Cancers driven by the oncogenic activation of the ALK gene include subsets of non-small cell lung cancer, lymphoma, neuroblastoma, melanoma, glioblastoma, thyroid cancer, stromal tumors and other hematologic malignancies and solid tumors. Typically, these cancers affect...</teaser>
  <objective>Cancers driven by the oncogenic activation of the ALK gene include subsets of non-small cell lung cancer, lymphoma, neuroblastoma, melanoma, glioblastoma, thyroid cancer, stromal tumors and other hematologic malignancies and solid tumors. Typically, these cancers affect children or young adults in healthy conditions with a long expectancy of life. They are currently treated with ALK tyrosine kinase inhibitors (TKIs) either in first line or at relapse after other standard therapies. ALK TKIs reduce tumor burden dramatically, and often induce a prolonged state of minimal residual disease (MRD) resulting in several years of extended survival. Eventually, most ALK+ tumors become resistant to ALK TKIs by different mechanisms. Relapses occur in &gt;90% of patients that are then left without efficacious therapies and face a dismal prognosis. This common pattern of evolution of ALK+ tumors, characterized by a prolonged state MRD before the fatal relapse, provides a window of opportunity to develop therapies that might be curative should ALK+ persister cells be fully eradicated. 
In this proposal, we will develop, test and validate a portfolio of ALK-directed T cell immunotherapies to achieve eradication of residual ALK+ cells during the MRD state induced by ALK TKIs. These immunotherapies include potentiated ALK.CAR-T cells for tumors that express ALK on the surface, and ALK.TCR-T cells for tumors that express ALK internally in the cytoplasm. ALK-directed T cell immunotherapies will be tested alone or in novel modalities of combination between them, with ALK vaccines or with other approaches to further potentiate their anti-tumoral efficacy. We will empower these ALK immunotherapies to eradicate MRD based on the ALK genetic alteration that is specific to each tumor. We envision that the combination of ALK TKIs with ALK-directed T cell immunotherapies could achieve a complete cure in a large subset of patients with ALK+ tumors before the onset of relapse or metastatic spread.</objective>
  <title>ALK-driven cancers: a Portfolio of ONcoimmunoTherapies to achieve tumor Eradication</title>
  <totalCost>0</totalCost>
  <ecMaxContribution>2497392</ecMaxContribution>
  <startDate>2026-01-01</startDate>
  <endDate>2030-12-31</endDate>
  <ecSignatureDate>2025-07-25</ecSignatureDate>
  <duration>60</duration>
  <status>SIGNED</status>
  <keywords>ALK cancer, CAR-T, TCR-T, cellular immunotherapies for cancer, cancer vaccines, lung cancer, lymphoma, neuroblastoma</keywords>
  <identifiers>
    <grantDoi>10.3030/101199997</grantDoi>
  </identifiers>
  <validation>
    <euroSciVoc>false</euroSciVoc>
  </validation>
  <sourceUpdateDate>2025-07-30 14:50:22</sourceUpdateDate>
  <contentCreationDate>2025-07-31 13:34:25</contentCreationDate>
  <contentUpdateDate>2025-07-31 13:34:23</contentUpdateDate>
  <lastUpdateDate>2025-11-12 15:02:02</lastUpdateDate>
  <relations>
    <associations>
      <article source="editorial" type="relatedArticle">
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <rcn>460135</rcn>
        <id>460135-targeting-residual-alk-positive-cancer-cells</id>
        <title>Targeting residual ALK-positive cancer cells</title>
        <contentUpdateDate>2025-11-12 15:02:00</contentUpdateDate>
        <relations>
          <categories>
            <category classification="applicationDomain" type="isApplicableIn">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/health</code>
              <title>Health</title>
              <displayCode>/Health</displayCode>
            </category>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/projectDescription</code>
              <title>Project description</title>
              <description>Article: description of linked project written by editorial team</description>
              <displayCode>/Project description</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/editorial</code>
              <title>CORDIS Editorial</title>
              <description>Written by CORDIS</description>
              <displayCode>/CORDIS Editorial</displayCode>
            </category>
          </categories>
        </relations>
      </article>
      <call source="corda" type="relatedMasterCall">
        <rcn>56633</rcn>
        <title>ERC-2024-ADG</title>
        <identifier>ERC-2024-ADG</identifier>
      </call>
      <call source="corda" type="relatedSubCall">
        <rcn>56633</rcn>
        <title>ERC-2024-ADG</title>
        <identifier>ERC-2024-ADG</identifier>
      </call>
      <organization netEcContribution="2497392" totalCost="0" source="corda" order="1" ecContribution="2497392" terminated="false" sme="false" type="coordinator">
        <availableLanguages>en</availableLanguages>
        <rcn>1907543</rcn>
        <id>999861936</id>
        <vatNumber>IT02099550010</vatNumber>
        <legalName>UNIVERSITA DEGLI STUDI DI TORINO</legalName>
        <shortName>UNITO</shortName>
        <address>
          <street>VIA GIUSEPPE VERDI 8</street>
          <city>TORINO</city>
          <postalCode>10124</postalCode>
          <country>IT</country>
          <postBox>N/A</postBox>
          <url>http://www.unito.it</url>
          <geolocation>45.0696399,7.6890729</geolocation>
        </address>
        <relations>
          <categories>
            <category classification="organizationActivityType" type="relatedOrganizationActivityType">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/HES</code>
              <title>Higher or Secondary Education Establishments</title>
              <displayCode>/Higher or Secondary Education Establishments</displayCode>
            </category>
          </categories>
          <regions>
            <region type="relatedNutsCode">
              <name>Torino</name>
              <rcn>309641281</rcn>
              <nutsCode>ITC11</nutsCode>
              <parents>
                <region>
                  <name>Piemonte</name>
                  <rcn>309641320</rcn>
                  <nutsCode>ITC1</nutsCode>
                  <parents>
                    <region>
                      <name>Nord-Ovest</name>
                      <rcn>309643816</rcn>
                      <nutsCode>ITC</nutsCode>
                      <parents>
                        <region>
                          <name>Italy</name>
                          <rcn>309758504</rcn>
                          <nutsCode>IT</nutsCode>
                          <euCode>IT</euCode>
                          <isoCode>IT</isoCode>
                        </region>
                      </parents>
                    </region>
                  </parents>
                </region>
              </parents>
            </region>
            <region type="relatedRegion">
              <name>Italy</name>
              <rcn>309758504</rcn>
              <nutsCode>IT</nutsCode>
              <euCode>IT</euCode>
              <isoCode>IT</isoCode>
            </region>
          </regions>
        </relations>
      </organization>
      <programme type="relatedLegalBasis" source="corda" uniqueProgrammePart="true">
        <availableLanguages>en</availableLanguages>
        <rcn>705727</rcn>
        <id>HORIZON.1.1</id>
        <code>HORIZON.1.1</code>
        <frameworkProgramme>HORIZON</frameworkProgramme>
        <pga>HORIZON.1.1</pga>
        <title>European Research Council (ERC)</title>
        <parent>
          <programme>
            <rcn>705726</rcn>
            <code>HORIZON.1</code>
            <parent>
              <programme>
                <rcn>705725</rcn>
                <code>HORIZON</code>
              </programme>
            </parent>
          </programme>
        </parent>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/legalbasis</code>
              <title>Legal Basis</title>
              <description>Programme: Legal basis for research funding</description>
              <displayCode>/Legal Basis</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </programme>
      <programme type="relatedTopic" source="corda">
        <availableLanguages>en</availableLanguages>
        <rcn>708726</rcn>
        <id>HORIZON_ERC-2024-ADG</id>
        <code>ERC-2024-ADG</code>
        <frameworkProgramme>HORIZON</frameworkProgramme>
        <title>ERC ADVANCED GRANTS</title>
        <parent>
          <programme>
            <rcn>20300</rcn>
            <code>HORIZON-Topics</code>
          </programme>
        </parent>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/topic</code>
              <title>Topic</title>
              <description>Programme: Part of the Commission work programme implementing legal basis</description>
              <displayCode>/Topic</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </programme>
    </associations>
    <categories>
      <category classification="collection" type="belongsTo">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/project</code>
        <title>Project</title>
        <description>Project factsheets</description>
        <displayCode>/Project</displayCode>
      </category>
      <category classification="euroSciVoc" type="isInFieldOfScience">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/21/39/225/1465/1801</code>
        <title>melanoma</title>
        <displayCode>/medical and health sciences/clinical medicine/oncology/skin cancer/melanoma</displayCode>
      </category>
      <category classification="euroSciVoc" type="isInFieldOfScience">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/21/35/159/653/1439</code>
        <title>vaccines</title>
        <displayCode>/medical and health sciences/basic medicine/pharmacology and pharmacy/pharmaceutical drugs/vaccines</displayCode>
      </category>
      <category classification="euroSciVoc" type="isInFieldOfScience">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/21/35/155/643</code>
        <title>immunotherapy</title>
        <displayCode>/medical and health sciences/basic medicine/immunology/immunotherapy</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/digitalAgenda</code>
        <title>Digital agenda</title>
        <description>This tracker monitors Horizon Europe’s financial contribution to the development of digital technologies and the digitisation of the economy and society (known as ‘Digital transition’).</description>
        <displayCode>/Digital agenda</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/cleanAir</code>
        <title>Clean air</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to the clean air policy (National Emission Ceiling Directive) aiming to improve ambient air quality and tackle air pollution, to protect the environment and human health.</description>
        <displayCode>/Clean air</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/ai</code>
        <title>Artificial intelligence</title>
        <description>This tracker monitors Horizon Europe’s financial contribution to the development and deployment of AI-based technologies and solutions. Projects that develop AI-tools as part of their research method are included</description>
        <displayCode>/Artificial intelligence</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/climate</code>
        <title>Climate action</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to both mitigating climate change (e.g., contributions to the reduction of greenhouse gas emissions) and adapting to climate change by building resilience (e.g., regarding floods, droughts, spatial planning and better governance, adaptation to changing climate in value chains, etc.).</description>
        <displayCode>/Climate action</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/biodiversity</code>
        <title>Biodiversity</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to Europe’s biodiversity’s path to recovery including species protection, ecosystem conservation, and habitat rehabilitation, all essential for resilience in climate adaptation and addressing ecosystem services but also environmental crime and the health-environment connection.</description>
        <displayCode>/Biodiversity</displayCode>
      </category>
      <category classification="projectFundingSchemeCategory" type="relatedProjectFundingSchemeCategory">
        <language>en</language>
        <availableLanguages>en</availableLanguages>
        <code>/HORIZON-ERC</code>
        <title>HORIZON ERC Grants</title>
        <description>HORIZON ERC Grants</description>
        <displayCode>/HORIZON ERC Grants</displayCode>
      </category>
      <category classification="source" type="isProvidedBy">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/corda</code>
        <title>CORDA</title>
        <description>RTD research data warehouse</description>
        <displayCode>/CORDA</displayCode>
      </category>
    </categories>
  </relations>
</project>